Gracell Biotechnologies, Inc.

NASDAQ:

GRCL

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.

Key Facts

Auditor

Public Listing

Domicile

HQ/Management

Location of Key Operations

IR Contact

PricewaterhouseCoopers Zhong Tian LLP

IPO (January 7, 2021)

Cayman Islands

Suzhou, China

Gracie Tong, Internal

Analyst Coverage

Latest News